Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 5/20 | 0.44 |
| ▸ | EGFR | P00533 | 4/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.44 |
| ▸ | IGF1R | P08069 | 2/20 | 0.44 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.38 |
| ▸ | RAF1 | P04049 | 4/20 | 0.37 |
| ▸ | PLK4 | O00444 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | GLB1 | P16278 | 1/20 | 0.35 |
| ▸ | CTRC | Q99895 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5362803 | 0.86 | PLK4 (0.47) | ERBB2EGFRPDGFRBIGF1RNOX4 | |
| SCHEMBL7139597 | 0.86 | EGFR (0.40) | ERBB2EGFRPDGFRBIGF1RNOX4 | |
| SCHEMBL7136206 | 0.83 | RET (0.50) | ERBB2PDGFRBIGF1RRETLRRK2 | |
| SCHEMBL5369299 | 0.82 | EGFR (0.59) | ERBB2EGFRPDGFRBIGF1RNOX4 | |
| SCHEMBL5377025 | 0.79 | RET (0.54) | ERBB2EGFRPDGFRBIGF1RRET | |
| SCHEMBL5364415 | 0.77 | EGFR (0.45) | ERBB2EGFRPDGFRBIGF1RNOX4 | |
| SCHEMBL7130522 | 0.76 | ADAMTS5 (0.51) | RETLRRK2NTRK1 | |
| SCHEMBL7137544 | 0.76 | LRRK2 (0.49) | EGFRRETLRRK2RAF1PLK4 | |
| SCHEMBL7133306 | 0.76 | ADAMTS5 (0.50) | RETLRRK2NTRK1 | |
| SCHEMBL7134866 | 0.76 | LRRK2 (0.50) | RETLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | ERBB2 19/4885EGFR 286/4885PDGFRB 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.